An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.

Andrew W Hahn Daniel J George Archana M Agarwal

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.See related article by Terry et al., p. xxx.

Keyphrases

metastatic renal cell carcinoma
tyrosine kinase
poor prognosis
binding protein
long non coding rna
type diabetes
stem cells
metabolic syndrome
risk assessment
drug induced
human health